BSX-PA Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Mai 2023 @ 22:00):

Stats
Tagesvolumen	2.06M
Durchschnittsvolumen	191 486
Marktkapitalisierung	175.45B
EPS	$0.342 ( 2023-09-29 )
Last Dividend	$1.375 ( 2023-05-12 )
Next Dividend	$0 ( N/A )
P/E	230.53
ATR14	$1.907 (1.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Fitzgerald Joseph Michael	Sell	11 660	Common Stock
2024-01-09	Mirviss Jeffrey B.	Buy	15 172	Common Stock
2024-01-09	Mirviss Jeffrey B.	Sell	15 172	Common Stock
2024-01-09	Mirviss Jeffrey B.	Sell	15 172	Stock Option (Right to Buy)
2024-01-04	Mirviss Jeffrey B.	Buy	15 000	Common Stock

INSIDER POWER
-33.84
Last 100 transactions
Buy: 835 783 \| Sell: 1 712 211

Volumen Korrelation

Lang: 0.29 (neutral)

Kurz: -0.14 (neutral)

Signal:(43.702) Neutral

Boston Scientific Korrelation

10 Am meisten positiv korreliert
DTC	0.915
CRD-B	0.903
OR	0.901
CRD-A	0.895
NGG	0.889
IBA	0.889
SQSP	0.877
AGI	0.876
BEST	0.874
USX	0.873

10 Am meisten negativ korreliert
CBU	-0.894
SFUN	-0.888
FRC-PI	-0.869
GLOP-PC	-0.868
FRC-PH	-0.867
ASPN	-0.865
TDCX	-0.865
FRC-PM	-0.864
FRC-PN	-0.861
FRC-PK	-0.861

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Boston Scientific Korrelation - Währung/Rohstoff

0.37
( neutral )

0.81
( strong )

0.11
( neutral )

0.25
( neutral )

-0.81
( strong negative )

Boston Scientific Finanzdaten

Annual	2023
Umsatz:	$14.24B
Bruttogewinn:	$9.90B (69.49 %)
EPS:	$1.080

FY	2023
Umsatz:	$14.24B
Bruttogewinn:	$9.90B (69.49 %)
EPS:	$1.080

FY	2022
Umsatz:	$12.68B
Bruttogewinn:	$8.68B (68.44 %)
EPS:	$0.450

FY	2021
Umsatz:	$11.89B
Bruttogewinn:	$8.13B (68.37 %)
EPS:	$0

Financial Reports:

No articles found.

Boston Scientific Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.375 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Boston Scientific Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.85 - good (98.54%) | Divividend Growth Potential Score: 3.91 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.436	2020-08-13
Last Dividend	$1.375	2023-05-12
Next Dividend	$0	N/A
Payout Date	2023-06-01
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$8.31	--
Avg. Dividend % Per Year	1.01%	--
Score	3.03	--
Div. Sustainability Score	9.85
Div.Growth Potential Score	3.91
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-05-27)

$1.395 Estimate 3.46 %

Dividend Stability

0.28 Very Poor

Dividend Score

3.03

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	$2.81	2.70%
2021	$4.13	3.80%
2022	$0	0.00%
2023	$1.375	1.21%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.121	1.500	7.59	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0505	1.200	8.32	9.98	[0 - 0.3]
returnOnEquityTTM	0.0955	1.500	-0.0497	-0.0746	[0.1 - 1]
payoutRatioTTM	0.0158	-1.000	9.84	-9.84	[0 - 1]
currentRatioTTM	1.320	0.800	8.40	6.72	[1 - 3]
quickRatioTTM	0.627	0.800	-1.018	-0.814	[0.8 - 2.5]
cashRatioTTM	0.175	1.500	-0.137	-0.205	[0.2 - 2]
debtRatioTTM	0.270	-1.500	5.50	-8.25	[0 - 0.6]
interestCoverageTTM	9.20	1.000	7.70	7.70	[3 - 30]
operatingCashFlowPerShareTTM	1.705	2.00	9.43	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.160	2.00	9.42	10.00	[0 - 20]
debtEquityRatioTTM	0.492	-1.500	8.03	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.691	1.000	1.809	1.809	[0.2 - 0.8]
operatingProfitMarginTTM	0.169	1.000	8.62	8.62	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.264	1.000	9.65	9.65	[0.2 - 2]
assetTurnoverTTM	0.419	0.800	-0.543	-0.434	[0.5 - 2]
Total Score				9.85

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	59.80	1.000	4.06	0	[1 - 100]
returnOnEquityTTM	0.0955	2.50	-0.0320	-0.0746	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.160	2.00	9.61	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.705	2.00	9.43	10.00	[0 - 30]
payoutRatioTTM	0.0158	1.500	9.84	-9.84	[0 - 1]
pegRatioTTM	0.186	1.500	-2.09	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.170	1.000	8.25	0	[0.1 - 0.5]
Total Score				3.91

Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.